نتایج جستجو برای: 6174delt

تعداد نتایج: 65  

Journal: :Archives of pathology & laboratory medicine 2006
Scott D Dufresne Dorothy R Belloni Wendy A Wells Gregory J Tsongalis

CONTEXT Real-time polymerase chain reaction technologies have replaced many of the more labor-intense methods in the molecular diagnostics laboratory. Similarly, melt curve analysis can provide a rapid means of mutation screening. OBJECTIVE To determine if real-time polymerase chain reaction and melt curve analysis using the SmartCycler II could be used as a screening tool for 3 common mutati...

Journal: :Annals of oncology : official journal of the European Society for Medical Oncology 2011
O Lavie S Narod F Lejbkowicz S Dishon Y Goldberg O Gemer G Rennert

BACKGROUND The frequency and characteristics of disease in individuals who concomitantly harbor pathogenic mutations in both BRCA1 and BRCA2 genes are not established. MATERIALS AND METHODS Data were collected from the database of Clalit Health Services National Familial Cancer Consultation Service. Probands referred to this clinical service and their family members are routinely tested for t...

2010
Mia M. Gaudet Tomas Kirchhoff Todd Green Joseph Vijai Joshua M. Korn Candace Guiducci Ayellet V. Segrè Kate McGee Lesley McGuffog Christiana Kartsonaki Jonathan Morrison Sue Healey Olga M. Sinilnikova Dominique Stoppa-Lyonnet Sylvie Mazoyer Marion Gauthier-Villars Hagay Sobol Michel Longy Marc Frenay GEMO Study Collaborators Frans B. L. Hogervorst Matti A. Rookus J. Margriet Collée Nicoline Hoogerbrugge Kees E. P. van Roozendaal Marion Piedmonte Wendy Rubinstein Stacy Nerenstone Linda Van Le Stephanie V. Blank Trinidad Caldés Miguel de la Hoya Heli Nevanlinna Kristiina Aittomäki Conxi Lazaro Ignacio Blanco Adalgeir Arason Oskar T. Johannsson Rosa B. Barkardottir Peter Devilee Olofunmilayo I. Olopade Susan L. Neuhausen Xianshu Wang Zachary S. Fredericksen Paolo Peterlongo Siranoush Manoukian Monica Barile Alessandra Viel Paolo Radice Catherine M. Phelan Steven Narod Gad Rennert Flavio Lejbkowicz Anath Flugelman Irene L. Andrulis Gord Glendon Hilmi Ozcelik Amanda E. Toland Marco Montagna Emma D'Andrea Eitan Friedman Yael Laitman Ake Borg Mary Beattie Susan J. Ramus Susan M. Domchek Katherine L. Nathanson Tim Rebbeck Amanda B. Spurdle Xiaoqing Chen Helene Holland Esther M. John John L. Hopper Saundra S. Buys Mary B. Daly Melissa C. Southey Mary Beth Terry Nadine Tung Thomas V. Overeem Hansen Finn C. Nielsen Mark I. Greene Phuong L. Mai Ana Osorio Mercedes Durán Raquel Andres Javier Benítez Jeffrey N. Weitzel Judy Garber Ute Hamann Susan Peock Margaret Cook Clare Oliver Debra Frost Radka Platte D. Gareth Evans Fiona Lalloo Ros Eeles Louise Izatt Lisa Walker Jacqueline Eason Julian Barwell Andrew K. Godwin Rita K. Schmutzler Barbara Wappenschmidt Stefanie Engert Norbert Arnold Dorothea Gadzicki Michael Dean Bert Gold Robert J. Klein Fergus J. Couch Georgia Chenevix-Trench Douglas F. Easton Mark J. Daly Antonis C. Antoniou David M. Altshuler Kenneth Offit

The considerable uncertainty regarding cancer risks associated with inherited mutations of BRCA2 is due to unknown factors. To investigate whether common genetic variants modify penetrance for BRCA2 mutation carriers, we undertook a two-staged genome-wide association study in BRCA2 mutation carriers. In stage 1 using the Affymetrix 6.0 platform, 592,163 filtered SNPs genotyped were available on...

2016
Abdulla Abdikhakimov Mukaddas Tukhtaboeva Bakhtiyar Adilov Shahlo Turdikulova

Introuduction Breast cancer is the most common malignancy in women and affects approximately 1 out of 8 females in the US. Risk of developing breast cancer is strongly influenced by genetic factors. Germ-line mutations in BRCA1 and BRCA2 genes are associated with 5-10% of breast cancer incidence. To reduce the risk of developing cancer and to increase the likelihood of early detection, carriers...

Journal: :Genetic epidemiology 2006
Nathan A Ellis Tomas Kirchhoff Nandita Mitra Tian-Zhang Ye Shaokun Chuai Helen Huang Khedoudja Nafa Larry Norton Susan Neuhausen Derek Gordon Jeffery P Struewing Steven Narod Kenneth Offit

We studied the feasibility of a novel approach to localize breast cancer susceptibility genes, using a low-density genome-wide panel of single-nucleotide polymorphisms and taking advantage of large regions of linkage disequilibrium (LD) flanking Jewish disease genes in high-risk cases. With Affymetrix GeneChip arrays, we genotyped 8,576 polymorphisms in three sets of Ashkenazi Jewish breast can...

Journal: :Journal of medical genetics 1998
F Lalloo S Cochrane B Bulman J Varley R Elles A Howell D G Evans

OBJECTIVES In view of the recent reports of recurrent mutations in BRCA1 and BRCA2 in the Ashkenazi Jewish population, we have undertaken to assess the frequency of these mutations in this population attending for genetic counselling and risk assessment of familial breast cancer. DESIGN Mutation screening for the 185delAG and the 5382insC mutations in BRCA1 and the 6174delT mutation in BRCA2 ...

Journal: :Hereditary Cancer in Clinical Practice 2009
Evgeny N Suspitsin Nathalia Yu Sherina Daria N Ponomariova Anna P Sokolenko Aglaya G Iyevleva Tatyana V Gorodnova Olga A Zaitseva Olga S Yatsuk Alexandr V Togo Nathalia N Tkachenko Grigory A Shiyanov Oksana S Lobeiko Nadezhda Yu Krylova Dmitry E Matsko Sergey Ya Maximov Adel F Urmancheyeva Nathalia V Porhanova Evgeny N Imyanitov

BACKGROUND A significant portion of ovarian cancer (OC) cases is caused by germ-line mutations in BRCA1 or BRCA2 genes. BRCA testing is cheap in populations with founder effect and therefore recommended for all patients with OC diagnosis. Recurrent mutations constitute the vast majority of BRCA defects in Russia, however their impact in OC morbidity has not been yet systematically studied. Furt...

Journal: :Cancer research 1997
G Ursin B E Henderson R W Haile M C Pike N Zhou A Diep L Bernstein

We conducted a study to determine whether the risk of breast cancer associated with oral contraceptive (OC) use is higher in women with BRCA1/BRCA2 mutations than in other women by examining whether breast cancer patients with these mutations were more likely than breast cancer patients without mutations in BRCA1/BRCA2 to have used OCs. We tested for BRCA1 185delAG and 5382insC and BRCA2 6174de...

Journal: :Cancer research 2002
Daphne W Bell John Erban Dennis C Sgroi Daniel A Haber

Carriers of one mutant allele of either BRCA1 or BRCA2 are at risk for somatic loss of the second wild-type allele, leading to the initiation of breast tumorigenesis. We identified a patient of Ashkenazi Jewish heritage with germ-line heterozygous mutations in both BRCA1 (5382insC) and BRCA2 (6174delT), who had developed three independent breast cancers by age 47. Two breast cancers demonstrate...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید